137 related articles for article (PubMed ID: 33088975)
1. Therapeutic effect of TRC105 and decitabine combination in AML xenografts.
Baik J; Felices M; Yingst A; Theuer CP; Verneris MR; Miller JS; Perlingeiro R
Heliyon; 2020 Oct; 6(10):e05242. PubMed ID: 33088975
[TBL] [Abstract][Full Text] [Related]
2. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
Dourado KMC; Baik J; Oliveira VKP; Beltrame M; Yamamoto A; Theuer CP; Figueiredo CAV; Verneris MR; Perlingeiro RCR
Blood; 2017 May; 129(18):2526-2536. PubMed ID: 28351936
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
5. Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations.
Li L; Zhang X; Yu H; Zhang M; Xu M; Liu J; Fu Y; Meng H; Lyu C; Li X; Zhou J
Onco Targets Ther; 2018; 11():6863-6870. PubMed ID: 30349319
[TBL] [Abstract][Full Text] [Related]
6. Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia.
Feng S; Yuan Y; Lin Z; Li M; Ye D; Shi L; Li D; Zhao M; Meng C; He X; Wu S; Xiong F; Ye S; Yang J; Zhuang H; Hong L; Gao S
Exp Hematol Oncol; 2024 Feb; 13(1):19. PubMed ID: 38378601
[TBL] [Abstract][Full Text] [Related]
7. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract][Full Text] [Related]
8. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
[TBL] [Abstract][Full Text] [Related]
9. The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells.
Shi M; Xu F; Yang X; Bai Y; Niu J; Drokow EK; Chen M; Chen Y; Sun K
Cancer Manag Res; 2019; 11():8229-8238. PubMed ID: 31564981
[TBL] [Abstract][Full Text] [Related]
10. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Zhao WH; Zeng QC; Huang BT; Li BS; Chen RL
Leuk Res; 2015 Apr; 39(4):424-8. PubMed ID: 25721158
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
13. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
[TBL] [Abstract][Full Text] [Related]
14. Decitabine in the treatment of acute myeloid leukemia in elderly patients.
Malik P; Cashen AF
Cancer Manag Res; 2014; 6():53-61. PubMed ID: 24520204
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
16. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
17. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation.
Meier R; Greve G; Zimmer D; Bresser H; Berberich B; Langova R; Stomper J; Rubarth A; Feuerbach L; Lipka DB; Hey J; Grüning B; Brors B; Duyster J; Plass C; Becker H; Lübbert M
Blood Cancer J; 2022 Aug; 12(8):122. PubMed ID: 35995769
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine.
Tang LJ; Sun GK; Zhang TJ; Wu DH; Zhou JD; Ma BB; Xu ZJ; Wen XM; Chen Q; Yao DM; Qian J; Ma JC; Lin J
Cancer Cell Int; 2019; 19():177. PubMed ID: 31333331
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.
Mpakou V; Spathis A; Bouhla A; Mpazani E; Papageorgiou S; Gkontopoulos K; Glezou E; Thomopoulos T; Foukas P; Pappa V
Exp Ther Med; 2021 Mar; 21(3):195. PubMed ID: 33488804
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
